Tv Therapeutics (NASDAQ:VTVT) said on Monday that the U.S. FDA has lifted the clinical hold on cadisegliatin's clinical trial ...

vTv Therapeutics董事长、总裁兼首席执行官Paul Sekhri表示，公司期待重启三期临床试验，进一步评估cadisegliatin相比单独使用胰岛素在血糖控制和低血糖发生率方面的效果。cadisegliatin有望成为1型糖尿病首个口服胰岛素辅助疗法。

We are thrilled our cadisegliatin clinical program can resume following the lifting of the clinical hold by the U.S. Food and Drug ...

Clinical hold lifted for late stage cadisegliatin program for diabetesCATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to ...

HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Thursday reported a loss of $3.6 million in its fourth quarter. On a per-share basis, the High Point, North ...

FDA clears vTv's cadisegliatin trial, prompting a 27.87% stock surge as the company fast-tracks pivotal studies ...

Investing.com -- vTv Therapeutics Inc . (NASDAQ: VTVT )股价上涨15%，此前该公司宣布FDA已解除对其糖尿病药物Cadisegliatin项目的临床暂停令。周一早间交易曾暂时停牌，恢复交易后股价显著上涨。

Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...